Humacyte (NASDAQ:HUMA) Shares Gap Down to $7.91

Humacyte, Inc. (NASDAQ:HUMA)’s share price gapped down before the market opened on Monday . The stock had previously closed at $7.91, but opened at $6.99. Humacyte shares last traded at $7.46, with a volume of 634,524 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Benchmark reiterated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research report on Tuesday, July 2nd. BTIG Research lifted their price objective on Humacyte from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price objective on shares of Humacyte in a research note on Tuesday, July 2nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Humacyte presently has an average rating of “Moderate Buy” and a consensus price target of $8.60.

Humacyte Stock Performance

The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $787.15 million, a P/E ratio of -6.63 and a beta of 1.52. The company’s 50 day moving average is $6.93 and its 200-day moving average is $5.15.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Friday, May 10th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). As a group, equities analysts anticipate that Humacyte, Inc. will post -0.95 EPS for the current year.

Insider Buying and Selling at Humacyte

In other Humacyte news, Director Gordon M. Binder purchased 50,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was acquired at an average price of $6.78 per share, for a total transaction of $339,000.00. Following the purchase, the director now owns 160,000 shares of the company’s stock, valued at approximately $1,084,800. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Gordon M. Binder purchased 50,000 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was acquired at an average price of $6.78 per share, for a total transaction of $339,000.00. Following the purchase, the director now owns 160,000 shares of the company’s stock, valued at $1,084,800. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Heather Ledbetter Prichard sold 188,886 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $8.14, for a total value of $1,537,532.04. Following the completion of the sale, the chief operating officer now directly owns 2,625 shares of the company’s stock, valued at $21,367.50. The disclosure for this sale can be found here. Over the last quarter, insiders bought 54,412 shares of company stock valued at $369,107 and sold 1,628,820 shares valued at $12,464,121. Insiders own 23.10% of the company’s stock.

Institutional Trading of Humacyte

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Humacyte by 28.7% during the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after purchasing an additional 896,415 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after buying an additional 524,600 shares during the last quarter. Capstone Investment Advisors LLC purchased a new position in shares of Humacyte in the 1st quarter worth approximately $972,000. Private Advisor Group LLC grew its holdings in shares of Humacyte by 232.7% in the first quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock valued at $988,000 after acquiring an additional 222,144 shares in the last quarter. Finally, ARS Investment Partners LLC purchased a new stake in shares of Humacyte during the second quarter valued at approximately $559,000. Institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.